David Smadja/Wikipedia
Jun 7, 2025, 08:46
David Smadja: A Major Step Forward in The Fight Against Cancer-Related Thrombosis
David Smadja, Team Director “Endotheliopathy and hemostasis disorders” at INSERM The Paris Cardiovascular Research Center, shared a post on LinkedIn:
“A major step forward in the fight against cancer-related thrombosis!
In the journal VAINCRE LE CANCER – NRB, we take a look back at the API-CAT study, led by Prof. Isabelle Mahé (Louis Mourier Hospital AP-HP) and our team at PARCC – Inserm Endotheliopathy & Hemostasis Disorders.
Result? A reduced dose of apixaban is sufficient to prevent thromboembolic recurrence with less bleeding.
This is further proof that academic research is changing clinical practices. Proud to contribute to this breakthrough in the service of cancer patients.”
You can read a wide variety of new scientific posts in Hemostasis Today.
-
Nov 19, 2025, 18:03Andres Ricaurte Fajardo on a Strongyloides Stercoralis Hyperinfection with Thrombosis
-
Nov 19, 2025, 17:50Marilena Vrana Reflects on PPTA Europe’s Visits with Members and Stakeholders in 2025
-
Nov 19, 2025, 17:32Michael Makris Shares Insights from Global Forum Meeting of the WFH Meeting in Montreal
-
Nov 19, 2025, 17:14Yazan Abou Ismail Takes The Legacy Award from Qatar Foundation
-
Nov 19, 2025, 17:02Wolfgang Miesbach Shares Real-World Evidence on Eptacog Beta from Spain
-
Nov 19, 2025, 16:34Ishita Singh Reflects on Haematocon 2025: A Reminder of Her Commitment to The Journey
-
Nov 19, 2025, 16:23Mehdi Kashani: I’m Really Excited to Share Schistosite.com
-
Nov 19, 2025, 16:09A ”Meow-cyte” from Melaku Abay Muluneh or Why Microscopy Never Gets Old!
-
Nov 19, 2025, 15:56Cuilan Li on her Contribution to a Cutting-Edge Project in Polycythemia Vera